Spruce Biosciences to Participate in November Investor Conferences

Rhea-AI Summary

Spruce Biosciences, Inc. (NASDAQ: SPRB), a biopharmaceutical company focused on rare endocrine disorders, will participate in two investor conferences in November 2022. The conferences include the Credit Suisse 31st Annual Healthcare Conference from November 7-10, where the company will present on November 8 at 2:35 p.m. PT, and the Jefferies 2022 London Healthcare Conference from November 15-17, featuring 1x1 meetings. Webcast access and replays will be available on the company’s investor relations website.

SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in November.

• Credit Suisse 31^st Annual Healthcare Conference
  Date: November 7-10, 2022
  Format: Company presentation (November 8, 2022 at 2:35 p.m. PT) and 1x1 meetings
  
  
• Jefferies 2022 London Healthcare Conference
  Date: November 15-17, 2022
  Format: 1x1 meetings

Interested parties can access the webcast for conference presentations from the events section of the company’s investor relations website. A replay of the webcast will be available after the conclusion of the live presentation for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 60 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005936/en/

Media Contact

Will Zasadny

Canale Communications

(619) 961-8848

will.zasadny@canalecomm.com

media@sprucebiosciences.com

Investors

Xuan Yang

Solebury Strategic Communications

(415) 971-9412

xyang@soleburystrat.com

investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.

FAQ

What investor conferences will Spruce Biosciences participate in November 2022?

Spruce Biosciences will participate in the Credit Suisse 31st Annual Healthcare Conference from November 7-10 and the Jefferies 2022 London Healthcare Conference from November 15-17.

When is Spruce Biosciences' presentation at the Credit Suisse Conference?

Spruce Biosciences is scheduled to present on November 8, 2022, at 2:35 p.m. PT.

How can I access the conference presentations of Spruce Biosciences?

The conference presentations can be accessed via the events section of Spruce Biosciences' investor relations website.

What is the focus of Spruce Biosciences' product candidate tildacerfont?

Tildacerfont is being developed as a potential first non-steroidal therapy for classic congenital adrenal hyperplasia (CAH) and for women with polycystic ovary syndrome (PCOS).

What is the ticker symbol for Spruce Biosciences?

The ticker symbol for Spruce Biosciences is SPRB.